The future of biomarker driven trials looks promising, with continued advancements in genomic technologies and big data analytics. These advancements are expected to lead to the discovery of new biomarkers and the development of even more targeted therapies. Additionally, the integration of artificial intelligence and machine learning in analyzing large datasets may further enhance the precision and efficiency of these trials.
